Tag: Cancer: Lymphoma
Outcomes for R-CHOP Worse in Morning for Female Patients With Lymphoma
Progression-free, overall survival significantly lower for female patients receiving chemo mostly in morning
FDA Approves New Drug for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
The next-generation BTK inhibitor zanubrutinib showed greater progression-free survival and fewer side effects in phase 3 trial
Delay in Time to Antibiotics Permissible for Inpatient Neutropenic Fever
Time to antibiotics does not significantly affect overall survival at 180 days in patients with hematologic malignancy who develop inpatient neutropenic fever
ASH: Glofitamab Aids Relapsed, Refractory Diffuse Large B-Cell Lymphoma
39 percent of patients had a complete response, with median time to complete response of 42 days
Brentuximab Vedotin + Chemo Ups Event-Free Survival in Peds Hodgkin Lymphoma
Event-free survival rate higher in pediatric patients, but no difference seen in the percentage of patients receiving involved-site radiation therapy
Tumefactive Demyelinating Lesions, Sentinel Lesions of PCNSL Compared
Age of onset younger for tumefactive demyelinating lesions than for primary central nervous system lymphoma
Incidence of Cutaneous T-Cell Lymphoma Up in the U.S.
Overall incidence rate six times higher for patients aged 40 years or older versus younger than 40 years, but increase in CTCL rate significantly higher for those younger than 40 years
FDA Warns of Rare Cases of Certain Cancers Linked to Breast Implants
Federal regulators discovered reports of the cancers as part of a routine postmarket review
Polypharmacy Prevalent Among Older Adults With Blood Cancers
Taking eight or more medications strongly associated with frailty; odds of being prefrail, frail increased with each additional med
Survival Advantage Seen for A+ADV in Advanced Hodgkin Lymphoma
Progression-free survival longer for brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine versus ABVD
